Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00942682 · ClinicalTrials.gov registry record · Phase 1
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00942682 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT00942682, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.
Interventions
- DRUG Sorafenib
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00942682
The ClinicalTrials.gov registry entry for NCT00942682 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT00942682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00942682 about?
NCT00942682 is a clinical study titled "Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors". The purpose of this research study is to find out more about the combination of RAD001 and sorafenib such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating neuroendocrine tumors.
What is the current status of trial NCT00942682?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2009-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00942682?
The interventions under investigation include: Sorafenib (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00942682?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.